TUMOR-ANTIGENS CA-19.9, CA-125, AND CEA IN CARCINOMA OF THE UTERINE CERVIX

被引:60
作者
BORRAS, G
MOLINA, R
XERCAVINS, J
BALLESTA, A
IGLESIAS, J
机构
[1] UNIV BARCELONA,HOSP CLIN & PROV,DEPT CLIN BIOCHEM,BARCELONA,SPAIN
[2] UNIV BARCELONA,HOSP CLIN & PROV,DEPT GYNECOL,BARCELONA,SPAIN
关键词
D O I
10.1006/gyno.1995.1126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serum levels of carcinoembryonic antigen (CEA) and cancer antigens CA 125 and CA 19.9 were determined by immunoradiometric assay in 96 patients diagnosed of invasive carcinoma of the uterine cervix and 7 patients of cervical intraepithelial neoplasia, Elevated CEA levels were found in 33%, CA 19.9 in 32%, and CA 125 in 21.5% of invasive carcinoma patients. Specificity for each tumor marker was 98%. Increased CEA and CA 19.9 levels were found in relation to clinical stage. CA 125 and CA 19.9 mean levels were significantly higher in patients with adenocarcinoma compared with squamous cell carcinoma. Detection rate of CA 19.9 in stage III adenocarcinomas was higher than in stage III squamous cell carcinoma (50 vs 21%). Sensitivity of combined antigens was also higher for adenocarcinomas increasing 60% for CA 19.9 and/or CA 125 and to 70% of cases for one of the three tumor antigens, During follow-up of cases with no evidence of disease, antigen levels showed a tendency to decrease, but all cases with progressive disease, recurrence, or metastasis were detected by elevation of one of these three tumor antigens. In conclusion, CEA, CA 125, and CA 19.9 are useful markers for detection of cervical cancer and monitorization of clinical course of disease. CA 19.9 and CA 125 have been shown to be particularly useful in patients With adenocarcinoma. (C) 1995 Academic Press, Inc.
引用
收藏
页码:205 / 211
页数:7
相关论文
共 60 条
  • [1] GASTROINTESTINAL CANCER-ASSOCIATED ANTIGEN (GICA) IMMUNOREACTIVITY IN COLORECTAL-CARCINOMA IN RELATION TO PATIENT SURVIVAL
    ARENDS, JW
    WIGGERS, T
    VERSTIJNEN, C
    HILGERS, J
    BOSMAN, FT
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1984, 34 (02) : 193 - 196
  • [2] AVALL A, 1992, EUR J CANCER A, V28, P1695
  • [3] BALASCH J, 1980, ESTUDIO INMUNOLOGICO
  • [4] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER
    BAST, RC
    KLUG, TL
    STJOHN, E
    JENISON, E
    NILOFF, JM
    LAZARUS, H
    BERKOWITZ, RS
    LEAVITT, T
    GRIFFITHS, CT
    PARKER, L
    ZURAWSKI, VR
    KNAPP, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) : 883 - 887
  • [5] REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA
    BAST, RC
    FEENEY, M
    LAZARUS, H
    NADLER, LM
    COLVIN, RB
    KNAPP, RC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) : 1331 - 1337
  • [6] MONITORING HUMAN OVARIAN-CARCINOMA WITH A COMBINATION OF CA-125, CA-19-9, AND CARCINOEMBRYONIC ANTIGEN
    BAST, RC
    KLUG, TL
    SCHAETZL, E
    LAVIN, P
    NILOFF, JM
    GREBER, TF
    ZURAWSKI, VR
    KNAPP, RC
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1984, 149 (05) : 553 - 559
  • [7] Borras G., 1992, European Journal of Gynaecological Oncology, V13, P414
  • [8] CARCINOEMBRYONIC ANTIGEN (CEA) AND CARBOHYDRATE DETERMINANT 19-9 (CA 19-9) LOCALIZATION IN 121 PRIMARY AND METASTATIC OVARIAN-TUMORS - AN IMMUNOHISTOCHEMICAL STUDY WITH THE USE OF MONOCLONAL-ANTIBODIES
    CHARPIN, C
    BHAN, AK
    ZURAWSKI, VR
    SCULLY, RE
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1982, 1 (03) : 231 - 245
  • [9] DELVILLANO BC, 1983, CLIN CHEM, V29, P549
  • [10] DISAIA P J, 1975, Gynecologic Oncology, V3, P215, DOI 10.1016/S0090-8258(75)80006-0